Evidence map›Paper›PMID 36249041›Full record

ArticleFrontiers in oncology2022

The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy.

Yang Wang, Zhiqiang Song, Yuke Geng, Lei Gao, Lili Xu, Gusheng Tang, Xiong Ni, Li Chen, Jie Chen, Tao Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yang WangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Zhiqiang SongDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Yuke GengDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Lei GaoDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Lili XuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Gusheng TangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Xiong NiDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Li ChenDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Jie ChenDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Tao WangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Weijia FuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Dongge FengHuaDao Biopharma (Shanghai) Limited Corporation, Shanghai, China.
Xuejun YuHuaDao Biopharma (Shanghai) Limited Corporation, Shanghai, China.
Libing WangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Jianmin YangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematotoxicity is the most common long-term adverse event after chimeric antigen receptor T cell (CAR-T) therapy. Here, a total of 71 patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) or large B-cell lymphoma (LBCL) were used to develop an early hematotoxicity predictive model and verify the accuracy of this model. The incidences of early hematotoxicity at 3 month following CAR-T infusion in B-ALL and LBCL were 45.5% and 38.5%, respectively. Multivariate analyses revealed that the severity of cytokine release syndrome (CRS) was an independent risk factor affecting early hematotoxicity. The analysis between the peak cytokine levels and early hematotoxicity suggested that tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) were closely associated with early hematotoxicity. Then, an early predictive model of hematotoxicity was constructed based on the peak contents of TNF-α and CRP. This model could diagnose early hematotoxicity with positive predictive values of 87.7% and 85.0% in training and validation cohorts, respectively. Lastly, we constructed the nomogram for clinical practice to predict the risk of early hematotoxicity, which performed well compared with the observed probability. This early predictive model is instrumental in the risk stratification of CAR-T recipients with hematotoxicity and early intervention for high-risk patients.

Indexed as

acute lymphoblastic leukemiachimeric antigen receptor T cellearly predictive modelhematotoxicitylarge B-cell lymphomarisk factors

Identifiers

PMID36249041
PMCPMC9561932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.